You are here:
rivaroxaban (Xarelto) DVT
Advice
following a full submission:
rivaroxaban (Xarelto®) is accepted for use within NHS Scotland.
Indication under review: treatment of deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults.
Rivaroxaban has been shown to be non-inferior to standard anticoagulant therapy including a low molecular weight heparin in combination with a vitamin K antagonist for the treatment of proximal DVT and prevention of recurrence.
Experience with rivaroxaban in this indication for more than 12 months is limited therefore the cost-effectiveness of indefinite treatment has not been demonstrated.
Drug Details
| Drug Name: | rivaroxaban (Xarelto) DVT |
|---|---|
| SMC Drug ID: | 755/12 |
| Manufacturer: | Bayer plc/Bayer Schering Pharma |
| Indication: | For the treatment of DVT and prevention of recurrent DVT & pulmonary embolism following acute DVT in adults |
| BNF Category: | |
| Sub Category: | 2.8 Anticoagulants and protamine |
| Submission Type: | Full submission |
| Status: | Accepted |
| Date Advice Published: | 13 February 2012 |